Introduction

Major problem associated with conventional anti-cancer drugs such as DNA/RNA/ microtubule poisons is a serious un-avoidable side effect(s) such as hair-loss, suppression of immune system and loss of appetite. These side effects stem from the fact that these poisons kill mainly the fast-growing cells including the majority of malignant cells but also hair cells, bone-marrow cells and intestinal brush-border cells which divide rapidly. However, around the turn of this century, a few far more selective anti-cancer drugs have been developed. Among them is “Gleevec” that inhibits a few oncogenic Tyr-kinases such as ABL, PDGFR (Platelet-Derived Growth Factor Receptor) and KIT [1]. Gleevec cures a few specific types of cancers called CML (Chromical Myelogenous Leukemia) and GIST (Gastrointestinal Stromal Tumor) without any serious side effects. Unfortunately, however, these rare cancers represent less than 0.1 % of all human cancers. Thus, the remaining 99% of cancer patients need another set of “signalling therapeutics” that block selectively the oncogenic signal transducers such as TOR (Target of Rapamycin), PAK1 (RAC/CDC42-activated kinase 1) and ILK (Integrin-Linked Kinase), without affecting normal signal transducers.

Around two decades ago, PAK1 was recognized by us and others as an oncogenic kinase that is activated by oncogenic RAS mutants in solid tumors such as pancreatic, colon and lung cancers representing at least 30% of all human cancers. Knock-out or silencing of PAK1 gene in these RAS cancers strongly suppresses their malignant (anchorage-independent) growth, without any effect on the normal (anchorage-dependent) cell growth [2]. More recently we confirmed that PAK1-deficient mutant (RB689) of C. elegans lives 60% longer than the wild-type [3], clearly indicating that PAK1 is an ageing kinase which shortens the healthy lifespan of this worm. Although nobody has measured the lifespan of PAK1-deficient mice as yet, they look far healthier than the wild-type, being resistant to PAK1-dependent tumor growth [4] and LPS (Lipopolysaccharide)-induced inflammation [5].

In fact many distinct natural PAK1-blockers have been shown to extend the lifespan of small animals such as C. elegans, Drosophila and mice. Among them are PI-3 kinase (Age), TOR (Target of Rapamycin), PAK1 (RAC/CDC42-activated kinase 1) and ILK (Integrin-Linked Kinase). KO (Knock Out) of these genes extends the healthy lifespan, increases heat-endurance, and reduces brood size (fertility) of these small animals. In other words, there is a clear “trade-off” relationship between their fertility and survival. In this mini-review we focus mainly on natural or synthetic PAK1-blockers that affect both fertility and survival. Interestingly these PAK1-blockers are among anti-cancer reagents. Thus, unlike conventional anti-cancer drugs such as DNA/RNA/microtubule poisons, these PAK1-blockers could cure cancers without causing any side effects. Both melatonin and a bee product called propolis could serve as divide very sensitive and time-saving in vivo screening for potent PAK1-blockers that could cure cancers and many other PAK1-dependent diseases/disorders such as AD (Alzheimer’s disease) without any serious side effects.
herbal PAK1-blockers such as CAPE (Caffeic Acid Phenethyl Ester), ARC (Artepillin C) and nymphaeols from plants [7].

More recently, even a few distinct synthetic PAK1-blockers such as Minoxydil (MC) were also confirmed to extend the healthy lifespan of *C. elegans* [8] or *Drosophila* [9]. Among them 15K is so far the most potent elixir that extends the lifespan of *C. elegans* even at 50 nM [8]. These PAK1-blocking elixirs share a few other common phenotypes. First of all, they down-regulate the fertility of this worm by 70-80% [3,8]. More interestingly, they boost the heat-endurance of this worm several times [8]. After prolonged heat-shock treatment (at 35°C for 8 hrs), more than 50% of the control worms die in 24 hrs, but more than 50% of the 15K-treated worms survive for more than 8 days [8]. Thus, we would easily predict that 15K and many other potent PAK1-blockers could prevent us from a premature death (shorter life span) caused by the current “global warming” (heat-shock).

In this brief review we introduce several examples of “longevity-promoting” PAK1-blockers isolated from nature or chemical synthesized.

**Natural PAK1-blockers**

**Melatonin**

Melatonin is a circadian hormone released from pineal glands. Its synthesis starts normally around the sunset to induce sleep, and stops just before the sunrise every morning [6]. It is derived from another hormone called serotonin (Figure 1), and was originally identified as an anti-melanogenic compound by Prof. Aaron Lerner at Yale in 1953, and named “melatonin”, meaning “anti-melanogenic serotonin derivative” [6]. However, the molecular mechanism underlying its anti-melanogenic activity remained unknown for so long until recently. It is now almost certain that melatonin suppresses the melanin synthesis by blocking the oncogenic/ageing/melanogenic kinase PAK1 [10]. Thus, it was not an entirely big surprise that melatonin extends the healthy lifespan of *Drosophila* as well as mice and rats by 20% [11]. Although melatonin is currently used as the major sleeping-pill for re-adjusting the jet-lags of trans-continental flight passengers, it could be useful for many other purposes such as heat-shock.

However, one of the major problems with melatonin is that it’s poor bio-availability (water-insolubility). A decade ago, an oncologist identified as an anti-melanogenic compound by Prof. Aaron Lerner at Yale in 1953, and named “melatonin”, meaning “anti-melanogenic serotonin derivative” [6]. However, the molecular mechanism underlying its anti-melanogenic activity remained unknown for so long until recently. It is now almost certain that melatonin suppresses the melanin synthesis by blocking the oncogenic/ageing/melanogenic kinase PAK1 [10]. Thus, it was not an entirely big surprise that melatonin extends the healthy lifespan of *Drosophila* as well as mice and rats by 20% [11]. Although melatonin is currently used as the major sleeping-pill for re-adjusting the jet-lags of trans-continental flight passengers, it could be useful for many other purposes such as heat-shock.

However, one of the major problems with melatonin is that it’s high IC₅₀ (around 23 μM) against the growth of A549 cancer cell line, and we wonder if we could lower the IC₅₀ by increasing its cell-permeability. However, so far an expected increase in its cell-permeability alone by replacing its acetyl moiety with basic amino acids such as ARG does not affect its anti-cancer activity, raising the possibility that its primary anti-cancer target(s) is on cell-surface rather than in the cytoplasm (Ahn MR, Kim I, Maruta H et al, unpublished observation). Interestingly, however, melatonin (1-20 μM) was recently reported to protect the LPS (Lipopolysaccharide)-induced apoptosis of HUVECs (Human Umbilical Vein Endothelial Cells) by activating AMPK (AMP-activated kinase), an anti-oncogenic kinase in the cytoplasm [12]. Thus, we are currently examining whether the ARG-linkage of melatonin potentiates its anti-LPS effect or not. Furthermore it would be of great interest to test if the ARG-linkage boosts the elixir (longevity-promoting) activity of melatonin in *C. elegans*.

**Propolis**

Propolis is a bee product, alcohol-extract of honey comb, and has been used as a traditional medicine for over 4 thousand years since the ancient Egyptian era. It is among anti-biotics that are effective against both bacterial and viral infections. That is one of the major reasons why propolis was used for preparation of mummies of deceased royal families stored under pyramids for thousands years. Hypocrates, the father of medicine, in ancient Greece coined this bee product “Propolis” (”Pro” for protection and “Polis” for city or honey comb). However, chemical components in propolis vastly differ from one to another depending on regions where propolis is harvested. For example, propolis from Europe, Far-East, and Oceania is rich in CAPE (Caffeic Acid Phenethyl Ester) and CA (Caffeic Acid), whereas Brazilian green propolis is rich in ARC (Artepillin C), and those from Asia-Pacific subtropical areas such as Okinawa, Taiwan and Hawaii are rich in nymphaeols [7,13]. Nevertheless all propolis products share a very unique common biological property: blocking PAK1, the major oncogenic/ageing/melanogenic kinase, and basically no side effect [7,13].

In late 1980s, CAPE-based propolis was found to inhibit the growth of cancer cells, but not the normal cell growth [14]. Since then propolis has been used as an alternative cancer therapeutic for treatment of cancer patients who fail to respond to the conventional anti-cancer drugs (DNA/RNA/microtubule poisons). More recently propolis was shown to extend the healthy lifespan and boost the heat-endurance of *C. elegans* [3,15, 16]. One of the major problems associated with propolis is poor water-solubility (low bioavail-ability) and poor cell-permeability as well. In an attempt to overcome these problems, we have converted the COOH-bearing ARC and CA to 1,2,3-triazolyl ester via Click Chemistry (CC), boosting their cell-permeability and anti-cancer activity by 100-400 folds without loss of their water-solubility [17].

**Curcumin**

Curcumin is the major PAK1-blocking ingredient in Turmeric (Curcuma longa) and directly inhibits PAK1 with IC₅₀ around 16 μM [15]. It is chemically similar to CAPE, and inhibits the growth of a variety of cancer cells such as A549 with IC₅₀ around 23 μM [15]. Curcumin also has been shown to extend the lifespan of *Drosophila* [18]. The major problem/setback for clinical application of curcumin is its poor bio-availability (water-insolubility). A decade ago, an oncologist...
group led by Razelle Kurzrock at MD Anderson Cancer Center in Texas successfully potentiated the bioavailability of curcumin by liposomes for therapy of pancreatic/colon cancers [6], and according to their 2008 clinical trial report, this "liposome" recipe appears to work in clinical trials (phase II) for some advanced pancreatic cancer patients [6].

**Triptolide**

*Tripterium wilfordii*, sometimes called thunder god vine, is a vine used in traditional Chinese medicine. An extract of its leaves or stalks has been used for controlling rheumatoid arthritis and other inflammatory diseases. It has been used for birth control for men as well, as it inhibits the growth of sperms. However, in 1972, its major anti-cancer ingredient was identified by Bryan and his colleagues as a di-terpenoid called Triptolide (TPE), (Figure 2), and its activity against the growth of pancreatic cancer and AD (Alzheimer’s disease) has been revealed [19]. However, the molecular mechanism underlying its anti-cancer activity remained unknown till recently. In 2009, a Chinese group found that Triptolide inactivates PAK1 by inhibiting both RAC and JAK2 [20]. TPE inhibits the growth of pancreatic and colon cancer cells with IC\textsubscript{50} around 30 nM, and in vivo inhibits the growth of human pancreatic and colon cancer xenografts in mice with 0.3 mg/kg [20]. In 2017, we found that it extends the lifespan of *C. elegans* by 20% and boosts the heat-endurance at 140 µM, proving that TPE causes no serious side effect [21]. However, since it is water-insoluble, it is not suitable for clinical application. Thus, in 2015, a group at Minnesota University synthesized a water-soluble phosphoryl derivative of Triptolide called “Minnelide” [22], and its clinical trial (phase II) for pancreatic cancer has been initiated.

**Glaucarubinone**

Glaucarubinone is a triterpenoid/quassinoid derived from a bitter tree (*Simarou-baccae* family) in Amazon forest. The extract of this tree bark has been used as a traditional medicine by local Amazon people for treatment of a variety of diseases including malaria infection which is now proven to be PAK1-dependent. Around 1981, its major active ingredient was identified as glaucarubinone, and rather surprisingly, it was found to show a potent anti-cancer activity [23]. However, the molecular mechanism underlying its anti-cancer activity remained to be clarified until recently. In 2009, John Beutler’s group at NCI-Frederick found the first clue: this compound inhibits the function of AP-1, an oncogenic transcription factor called AP-1 in cancer cells with IC\textsubscript{50} around 20 nM [24]. Since AP-1 is downstream of PAK1, we started suspecting that it might be a PAK1-blocker. In collaboration with his team, we confirmed that glaucarubinone indeed blocks PAK1 in cell culture, and another group led by Hong He at Melbourne University Hospital found that it blocks both PAK1 and PAK4 in vivo, inhibiting the growth of human pancreatic and colon cancer xenograft in mice at 1-2 mg/kg, i.p. twice a week [25]. To the best of our knowledge, this compound is the most potent anti-cancer agent among herbal PAK1-blockers. Most interestingly, in 2011, a group at Jena University in Germany found that this compound at 1-10 nM extends the lifespan of *C. elegans*, suggesting that it would not cause any side effect during cancer therapy [26].

**Daumone**

Daumone is a dauer-inducing glucoylated pheromone (Figure 3) produced by *C. elegans* [27]. It was originally found to be a potent anti-cancer agent by a Korean group at Yonsei University led by Mankil Jung in 2005 [27]. It can be chemically synthesized as well. In 2009, this team managed to synthesize a very potent anti-cancer derivative from Daumone with IC\textsubscript{50} around 20 nM [28]. Later (in 2014), Daumone (2 mg/kg daily) was found by the same team to extend the healthy lifespan of mice by 50% [29]. Since Daumone or its derivatives inhibit strongly both PAK1-dependent inflammatory diseases and angiogenesis in ovo (CAM assay) as well [28], it is almost certain that Daumone also blocks PAK1 somehow, and we are planning to confirm this notion. More interestingly, Daumone bears a COOH moiety, and if it is esterized with the water-soluble triazolyl alcohol via Click Chemistry (CC), its anti-cancer activity could be boosted with a robust increase in its cell-permeability, as described earlier with a few other COOH-bearing PAK1-blockers such as ARC and CA [18].

**Synthetic PAK-blockers**

1,2,3-Triazolyl ester of ketorolac (15K)

Ketorolac, an old pain-killer, is a racemic mixture of R-form and S-form. R-form inhibits RAC, blocking PAK1 [30], while S-form directly inhibits COX-2 which is involved in the production of prostaglandin [30]. The growth of A549 cancer cells requires both PAK1 and its effector COX-2 [31]. However, just like Daumone, ARC, and CA, Ketorolac is among COOH-bearing PAK1-blockers whose cell-permeability is rather poor. Thus, we recently linked its COOH moiety to the water-soluble 1,2,3-triazolyl alcohol via CC, making a highly cell-permeable ester called "15K" (Figure 4). Both anti-cancer and anti-PAK1 activities of Ketorolac are boosted over 500 times by the "CC"-based esterization. In addition, its anti-COX-2 activity is boosted 20 fold, most likely due to the anti-COX-2 activity of 1,2,3-Triazolyl ring per se [31].

In ovo (CAM assay in fertilized chicken eggs), "15K" was shown to inhibit the angiogenesis with IC\textsubscript{50} = 1 nmol/egg [32]. Furthermore, "15K" (50 nM) extends the healthy lifespan of *C. elegans* by 15-30%, and boosts the heat-endurance by 10-fold even at 10 nM [8]. To the best of our knowledge, 15K is the most potent synthetic “elixir” (longevity-promoter).
Aspirin

The most popular Bayer product called Aspirin (acetylsalicylic acid) is the oldest semi-synthetic pain-killer originally derived from an herbal medicine called salicylic acid (SA). Interestingly, however, Aspirin was found to inhibit both inflammation and cancer growth with IC_{50} around 3 mM. A few years ago, a Chinese group reported that Aspirin extends the lifespan of *C. elegans* and boosts its heat-endurance [33]. Due to its COOH-moiety, however, its cell-permeability is rather poor. Thus, several years ago, via CC, Aspirin was also converted to 1,2,3-triazolyl ester. IC_{50} of this ester against the growth of A549 cancer cells is around 0.1 mM, 30 times lower than that of Aspirin.

Metformin

Metformin is an old synthetic anti-diabetic/anti-obesity compound. The major target of metformin is the anti-oncogenic LKB1-AMPK (AMP-activated kinase) cascade, and metformin activates AMPK with ED_{50} around 2 mM [34]. Interestingly, however, almost all AMPK activators inhibit PAK1 by activating LKB1 which in turn inactivates PAK1 [7]. Thus, it is most likely that Metformin is also among PAK1-blockers. A few years ago Metformin was shown to extend the healthy lifespan of *C. elegans* at 50 mM [35].

Minocycline

Minocycline (MC), (Figure 5) is an old semi-synthetic derivative of tetracycline developed as an improved antibiotic by Lederle in 1961 and came into commercial use in 1971. However, over decades, in addition to the anti-bacterial activity, MC has shown a variety of other pharmacological activities including an anti-cancer activity that inhibits the growth of A549 cancer cells with IC_{50} ranging 5-10 µM [36], as well as the PAK1-dependent blood-coagulation with apparent anti-MLKs (RAC/CDC42-activated kinases) activity [37]. Recently MC at 50 µM was found to extend the lifespan of *Drosophila* by 25% [38]. More recently, MC was reported to prevent cerebral malaria in mice [39], clearly indicating that MC passes through BBB (Blood-Brain Barrier). In support of this notion, MC has been shown to be effective clinically in promoting sleep-associated memory processing [40] and for treatment of brain tumors such as NF1-deficient MPNST [41]. Regarding the molecular mechanism underlying its anti-cancer, anti-malaria and elixir (longevity-promoting) activities, it is most likely that MC directly inhibits both PAK1 and MLKs, as does CEP-1347 [42].

Hydralazine

Hydralazine (Figure 6) is a medication used to treat high blood pressure and heart failure. It was originally developed by Chiba-Geigy for Malaria treatment and patented in 1949. Both malaria and hypertension are among PAK1-dependent diseases, it is most likely that hydralazine is among synthetic PAK1-blockers. Thus, it is not a surprize that hydralazine was recently found to extend the lifespan of *C. elegans* and induces stress-resistance as well [43].

Conclusion

The combination of both reduction of fertility and increase in heat-endurance of *C. elegans* could serve as the most sensitive (and time-saving) criteria (or indicators) for us to screen in vivo a variety of PAK1-blocking anti-cancer drugs/elixirs such as melatonin, propolis and 15K that do not cause any serious side effects. Furthermore, while PAK1-deficient mice are highly resistant to LPS-induced inflammation [5], CD300f-deficient mice are highly senstive to LPS-induced inflammation/atopy [44], strongly suggesting the possibility that CD300f, a ceramide receptor, is a natural PAK1-blocking tumor suppressor/elixir. Thus, a LPS-induced skin reaction/atopy at ears of CD300f-deficient mice could also serve as a rapid and inexpensive in vivo screening system for PAK1-blockers.

References

1. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood. 2008; 112: 4808-4817.
2. Tang Y, Chen Z, Ambrose D, Liu J, Gibbs HB, Chemoff J, et al. Kinase-deficient Pak1 mutants inhibit Ras transformation of Rat-1 fibroblasts, Mol. Cell. Biol. 1997; 17: 4454-4464.
3. Yanase S, Luo Y, Maruta H. PAK1-deficiency/down-regulation reduces brood size, activates HSP16.2 gene and extends lifespan in *C. elegans*, Drug Discov. Ther. 2013; 7: 29-35.
4. Huyrnh N, Liu KH, Baldwin GS, He H. p21-activated kinase 1 stimulates colon cancer cell growth and migration/invasion via ERK- and AKT-dependent pathways. Biochim Biophys Acta. 2010; 1803: 1106-1113.
5. Allen JD, Jaffer ZM, Park SJ, Burgin S, Hofmann C, Sells MA, et al. p21-
activated kinase regulates mast cell degranulation via effects on calcium mobilization and cytoskeletal dynamics, Blood. 2009; 113: 2695-2705.

6. R Reiter, J Robinson. Melatonin: Your Body’s Natural Wonder Drug. Bantam Books, New York, 1995.

7. H Maruta, Herbal Therapeutics that Block the Oncogenic Kinase PAK1: A Practical Approach towards PAK1-dependent Diseases and Longevity, Phytother. Res. 2014; 28: 656-672.

8. Nguyen BC, Kim SA, Won SM. 1,2,3-triazolyl ester of ketorolac (15K): Boosting both heat-endurance and lifespan of C. elegans by blocking PAK1. Drug Discov. Ther. 2018; 11.

9. Mora M, Medina-Leendertz SJ, Bonilla E, Terán RE, Paz MC, Arcaya JL. Minocycline, but not ascorbic acid, increases motor activity and extends the lifespan of Drosophila melanogaster. Invest. Clin. 2013; 54: 161-170.

10. Be-Tu PT, Nguyen BC, Tawata S, Yun CY, Kim EG, Maruta H. The serum/PGDF-dependent “melanogenic” role of the minute level of the oncogenic kinase PAK1 in melanoma cells proven by the highly sensitive kinase assay, Drug Discov. Ther. 2017; 10: 314-322.

11. Anisimov VN, Mylnikov SV, Khavinson VK. Pineal peptide preparation epithalamin increases the lifespan of fruit flies, mice and rats, Mech. Ageing Dev.1998; 84: 230-232.

12. Cui J, Li Z, Zhuang S, Qi S, Li L, Zhou J, et al. Melatonin alleviates inflammation-induced apoptosis in human umbilical vein endothelial cells via suppression of Ca2+–XO–ROS-Drp1-mitochondrial fission axis by activation of AMPK/SERCA2α pathway, Cell Stress Chaperones. 2017.

13. Nguyen BC, Yoshimura K, Kumazawa S, Tawata S, Maruta H. Frondoside A from Sea Cucumber and Nymphaea from Okinawa Propolis: Natural anti-cancer agents that selectively inhibit PAK1 in vitro, Drug Discov. Ther. 2017; 11: 110-114.

14. D Grunberger, R Banerjee, K Eisinger, EM Oltz, L Efron, M Caldwell, et al. Preferential cytotoxicity on tumor cells by caffeic acid phenethyl ester isolated from propolis, Experientia.1988; 44: 230-232.

15. Taira N, Nguyen BC, Be-Tu PT, Tawata S. Effect of Okinawa propolis on PAK1 activity, C. elegans longevity, melanogenesis, and growth of cancer cells, J. Agric. Food Chem. 2016; 64: 5484-5489.

16. Havermann S, Chovolou Y, Humpf HU, Wältjen W. Caffeic acid phenylester increases stress resistance and enhances lifespan in C. elegans by modulation of the insulin-like DAF-16 signalling pathway, PLoS One. 2014; 9.

17. Takahashi H, Nguyen BC, Uto Y, Shahinhozzamand MD, Tawata S, Maruta H. 1,2,3-Triazolyl esterization of PAK1-blocking propolis ingredients, artepillin C (ARC) and caffeic acid (CA), for boosting their anti-cancer/anti-PAK1 activities along with cell-permeability, Drug Discov. Ther. 2017; 11: 104-109.

18. Liao VH, Yu CW, Chu YJ, Li WH, Hsieh YC, Wang TT. Curcumin-mediated lifespan extension in C. elegans, Mech. Ageing Dev. 2011; 132: 480-487.

19. Kupchan SM, Court WA, Jr Dailey RG, Gilmore CJ, Bryan RF. Triptolide and tripropidol, novel antileukemic diterpenoid triepoxides from Tripterygium wilfordii, J. Am. Chem. Soc. 1972; 94: 7194-7195.

20. Wang Z, Jia H, Xu R, Me Q, Fan D. Triptolide downregulates Rac1 and the JAKSTAT3 pathway and inhibits colitis-related colon cancer progression, Exp. Mol. Med. 2009; 41: 717-727.

21. Kim SJ, Beak SM, Park SK, Supplementation with Triptolide Increases Resistance to Environmental Stressors and Lifespan in C. elegans, J. Food. Sci. 2017; 82: 1484-1490.

22. Patil S, Lis LG, Schumacher RJ, Norris BJ, Morgan ML, Cuellar RA, et al. Phosphonoxyoxymethyl Prodrug of Triptolide (Minnelide): Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts, J. Med. Chem. 2015; 58: 9334-9344.

23. Trager W, Polonsky J. Antimalarial activity of quassinoids against chloroquine-resistant Plasmodium falciparum in vitro, Am J Trop Med Hyg. 1981; 30: 531-537.

24. Beulter JA, Kang M, Robert F, Clement JA, Pelletier J, Colburn NH, et al. Quassinoid inhibition of AP-1 function does not correlate with cytotoxicity or protein synthesis inhibition, J Nat Prod. 2009; 72: 503-506.

25. Yeo D, Huynh N, Beulter JA, Christophi C, Shulkes A, Baldwin GS, et al. Glaucarubinone and Glaucalabine Synergistically Reduce Pancreatic Cancer Growth via Down-Regulation of PAKs, Cancer Lett. 2014; 346: 264-72.

26. Zarse K, Bossecker A, Müller-Kuhlt L, Siemers K, Hernandez MA, Berendsen WG, et al. The phytochemical glaucarubinone promotes mitochondrial metabolism, reduces body fat, and extends lifespan of C. elegans, Horm Metab Res. 2011; 43: 241-243.

27. Jeong PY, Jung M, Yim YH, Kim H, Park M, Hong E, et al. Chemical structure and biological activity of the C. elegans dauer-inducing pheromone, Nature. 2005; 433: 541-545.

28. Ricci J, Min D, Oh M, Lim H, Chung WY, Park KK, et al. Synthesis of daunomycin derivatives and their anti-angiogenic activities on chorioallantoic membrane, Med. Chem. 2015; 11: 747-752.

29. Park JH, Chung HY, Kim M, Lee JH, Jung M, Ha H. Daunomycin fed late in life improves survival and reduces hepatic inflammation and fibrosis in mice, Aging Cell. 2014; 13: 709-718.

30. Guo Y, Kenney Jr SR, Muller CY, Adams S, Rutledge T, Romero E, et al. R-ketorolac Targets Cdo42 and Rac1 and Alters Ovarian Cancer Cell Behavior: Critical for Invasion and Metastasis, Mol. Cancer Ther. 2015; 14: 2215-2227.

31. Nguyen BC, Takahashi H, Uto Y, Shahinhozzamand MD, Tawata S, Maruta H. 1,2,3-Triazolyl ester of Ketorolac: A “Click Chemistry”-based highly potent PAK1-blocking cancer-killer, Eur. J. Med. Chem. 2016; 123: 270-276.

32. Ahn MR, Bae JY, Jeong DH, Takahashi H, Uto Y, Maruta H. Both Triazolyl ester of Ketorolac (15K) and YM155 inhibit the embryonic angiogenesis in ovo (fertilized eggs) via their common PAK1-survivin/VEGF signaling pathway, Drug Discov. Ther. 2017; 11: 300-306.

33. Wan QL, Zheng SQ, Wu GS, Luo HR. Aspigin extends the lifespan of C. elegans via AMPK and DAF-16/FOXO in dietary restriction pathway, Exp Gerontol. 2013; 48: 499-506.

34. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action, J Clin Invest. 2001; 106: 1167-1174.

35. Haes W De, Froonincx K, Van Assche R, Smolders A, Depuydt G, Billen J, et al. Metformin promotes lifespan through mitohormesis via the peroxiredoxin PRDX-2, Proc Natl Acad Sci U S A. 2014; 111: E2501-2509.

36. Ko JC, Wang TJ, Chang PY, Syu JJ, Chen JC, Chen CY, et al. Minocycline enhances mitomycin C-induced cytotoxicity through down-regulating ERK1/2-mediated Rad51 expression in human non-small cell lung cancer cells, Biochem Pharmacol. 2015; 97: 331-340.

37. Jackson JW, Singh MV, Singh VB, Jones LD, Davidson GA, Ture S, et al. Novel Antiplatelet Activity of Minocycline Involves Inhibition of MLK3-p38 Mitogen Activated Protein Kinase Axis, PLoS One. 2016; 11: e0157115.

38. Mora M, Medina-Leendertz SJ, Bonilla E, Terán RE, Paz MC, Arcaya JL. Minocycline, but not ascorbic acid, increases motor activity and extends the lifespan of Drosophila melanogaster. Invest. Clin. 2013; 14: 161-170.

39. Apoorv TS, Babu PP. Minocycline prevents cerebral malaria, confers neuroprotection and increases survivability of mice during Plasmodium berghei ANKA infection, Cytokine. 2017; 90: 113-123.

40. Besedovsky L, Schmidt EM, Linz B, Diekelmann S, Lange T, Born J. Signs of enhanced sleep and sleep-associated memory processing following the anti-inflammatory antibiotic minocycline in men, J Psychopharmacol. 2017; 31: 204-210.

41. Lee MJ, Hung SH, Huang MC, Tsai T, Chen CT. Doxycycline potentiates the antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy in malignant peripheral nerve sheath tumor (MPNST) cells, PLoS One. 2017; 12: e0178483.
42. Nheu TV, He H, Hirokawa Y, Tamaki K, Florin L, Schmitz ML, et al. The K252a derivatives, inhibitors for the PAK/MLK kinase family selectively block the growth of RAS transformants. Cancer J. 2002; 8: 328-336.

43. Dehghan E, Zhang Y, Seremi B, Yadavali S, Hakimi A, Dehghani M, et al. Hydralazine induces stress resistance and extends C. elegans lifespan by activating the NRF2/SKN-1 signalling pathway, Nat Commun. 2017; 8: 2223.

44. Shiba E, Izawa K, Kaitani A, Isobe M, Maehara A, Uchida K, et al. Ceramide-CD300f Binding. Inhibits Lipopolysaccharide-induced Skin Inflammation, J Biol Chem. 2017; 292: 2924-2932.